George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Jonesrichard:
You say in your post
“ it will very very satisfying for genuine holders here to know that we are helping in these health areas whilst also making money at the same time.”
I hold 70,000 shares but I’m sorry I do not believe the cash I invested allows me to either claim or feel I am helping in these health areas. Avacta didn’t receive the funds I invested, that was simply liquidity for the market maker.
Mstar, I think you will still see huge publicity on all progress with other partnerships. In Alastair Smith’s company presentations he went through many of these in passing but news will come and the publicity from these projects will help Avacta’s global profile which will make news in the Lancet and other publications used in the world of medicine.
We will benefit too.
Cheers Rich
Dr Smith reported there are several undisclosed contracts and projects with other parties. I assume this will mean there may never be any news flow for these except for revenues flowing into the bank.
Yes Ken, Sir, we are all behind this amazing company and what it can become and the good it will do for human kind in the process.
Jonesrichard, a much higher market cap is coming over the months ahead, how it it gets and when is a question we cannot answer. The role of the worlds population in following instruction will decide if the virus spreads and how large the uptake will be for testing. It should be massive and our product should be key to global testing.
From my posts tonight you will be well aware where my priorities lie.
Thanks Rich
The share price is only what people veiw the companies worth and is willing to pay for it.
£10 would be great, and very possible with the pipline as it is atm. With more to come in the future. Royal Dutch shell was £25 last year. That is oil etc. This is game changing on so many levels, plus future covid outbreaks, 4 weeks for new affirmers to be developed, with more investment and better facilities that time surly could be reduced.
Thanks Ken, great posts as always, it certainly will be amazing when the companys Cancer therapeutics come to fruition along with our special test which seems to now be on the cusp of being released finally! it will very very satisfying for genuine holders here to know that we are helping in these health areas whilst also making money at the same time.
Are you still confident of a £10 sp by end of July here? only asking as you did put that out there a couple of months back if my memory serves me correctly, I'm presuming that you are more confident now than before?
Thanks for all you do Sir once again.
This is from the recent cash raise and this will accelerate Avacta’s potential:
- £10 million is ready for a rapid scale-up of Diagnostics Business,
- Working capital for the COVID-19 testing opportunity
- Expansion of in-house diagnostics product development capabilities including
facilities, capital equipment; scientific, commercial and senior leadership teams
- Acceleration of broader diagnostics product pipeline and commercial partnerships
-£38 million is ready to accelerate the Expansion of Pipeline of Differentiated Cancer Therapies:
- Rapidly growing the pre|CISION™ pre-clinical pipeline and delivering pre-clinical packages for several pro-drugs (pre|CISION™ velcade, paclitaxel and oxaliplatin).
- Expanding the Affimer® immunotherapy pipeline (PDL1-TGFß inhibitor and PDL1-cytokine bispecifics).
- IND/CTA filings for one or more Affimer immunotherapies (TMAC drug conjugate (PDL1-IDASH) or first bispecific candidate) and one or more pre|CISION pro-drugs.
- Obtain first-in-human data for the Affimer® platform.
- UK phase I clinical trial for first pre|CISION™ chemotherapy AVA6000 pro-doxorubicin covered by current cash reserves, with the proceeds of the Fundraise being used to fund IND filing AVA6000.
- Total Number of Shares is now 235,152,097
- Avacta has a new significant STRATEGIC US investor added to its shareholder base
- Employees are getting shares which will reward there hardwork
Alastair Smith and the Board "anticipates strong near-term news flow relating to the COVID-19 test developments with Cytiva and Adeptrix, as well as commercial and technical progress in the established therapeutic and diagnostics businesses, allowing the Company to concurrently achieve multiple value inflection points that we expect will deliver substantial shareholder returns. I look forward to updating the market on our continued progress."
I expect a very strong news flow and a new partnership which will really open up a very strong future for Avacta - Think pre|CISION™ Therapeutics!! Attaching drugs to Affimers and you have a precision drug warhead with reduced or no side effects! This is where the real value will come!
Cheers Rich